Insider buying last 90 days
No open-market insider purchases were filed for ARGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ARGX insider filing, plotted on the chart in Gekko.Open ARGX in Gekko
Gekko Brief
AI summaryNov 4 closeThis week's news centers on strong VYVGART momentum and upcoming investor visibility. argenx reported third-quarter 2026 results showing VYVGART sales rising 54% year-over-year to $1.721 billion, alongside growth in operating profit. Management is also scheduled to participate in two healthcare investor conferences in November, with fireside chats in Boston on November 10 and London on November 17, covering the company's immunology business and development portfolio. Separately, a law firm announced an investigation into investor claims tied to the company.
Shares closed at $931.38, up 3.4%, sitting between the 50-day average of $936.35 and the 200-day average of $856.15. The GekkoIndex reads 54.3, placing the stock in the Neutral zone, with its 5-day change down 4.8. The current price sits 9.1% below Gekko Fair Value of $1,025.11.
Over the next 20 trading days, the next earnings date falls on 25 February 2027, 112 days away, outside a typical holding window. In the last 30 days, one unusual options signal was recorded, with put premium of $1,081,500 against call premium of $223,125. Seasonally, the next 20 trading days have averaged -0.3% over 5 years, rising in 3 of them. Analyst sentiment remains heavily weighted toward buy ratings, with 19 of 20 firms at buy and a consensus target of $1,147.35.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
argenx price vs fair value
Close $931.38200-day averageGekko Fair Value $1,025.11
argenx quick facts
- Market cap
- $58.57B
- P/E ratio
- 31.1
- Forward P/E
- 25.6
- EPS, TTM
- $28.87
- Revenue, TTM
- $5.92B
- Profit margin
- 31.7%
- Dividend yield
- —
- Beta
- -0.04
- Volume
- 645,794 avg 523,616
- 1-year return
- +12.7%
- Typical daily move
- ±3%
- Typical 20-day move
- ±5.5%
- 50-day average
- $936.35
- 200-day average
- $856.15
- Next earnings
- Feb 25 before open
- Shares outstanding
- 62.89M
argenx swing-trade checklist
argenx scores 2 supportive, 3 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed1 headwind
- Trendmixed
Averages disagree
Close $931.38 sits between the 50-day ($936.35) and 200-day ($856.15) averages, or the averages disagree.
See the chart - GekkoIndexmixed
54.3, Neutral
Reading 54.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
9.1% below
Price is 9.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 112 days
Next report Feb 25, 2027, 112 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−0.3% on average
From this point in the calendar, the next 20 trading days averaged −0.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
argenx stock chart and price history
argenx closed at $931.38 on Nov 4, 2026, +12.7% over the past year, inside a 52-week range of $661.85 to $1,072.75.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.1%
- 3 months
- +6.4%
- 6 months
- +15.3%
- 1 year
- +12.7%
The full ARGX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ARGX in Gekko
Follow argenx through every session
Put ARGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ARGX in GekkoFree for 7 days. No credit card required.
About argenx
argenx works on medicines for people whose immune systems attack their own bodies, turning early research into treatments that reach patients. Its main therapy, efgartigimod, underpins the medicines it sells under the VYVGART, VYVGART HYTRULO and VYVDURA brands, currently used against nerve and blood disorders where the immune system is overactive, with additional uses under study in a long list of other conditions.
Alongside these approved products, the company keeps a wider set of experimental drugs moving through testing, among them empasiprubart, ARGX-119, ARGX-213 and other early-stage candidates aimed at different immune targets. Much of this work relies on outside partners: argenx has struck deals with companies such as AbbVie, Zai Lab and LEO Pharma, joined forces with Genmab on antibody research, and linked up with IQVIA for drug-safety support, plus various academic and research collaborators. Sales and trials reach patients across the Americas, Asia, Europe, the Middle East and Africa.
Founded in Amsterdam in 2008, argenx operates under the European public-company structure known as an SE. Its stock trades under the ticker ARGX.
- Sector
- Health technology
- Website
- argenx.com
argenx GekkoIndex: the smart money zone
argenx’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.3, in the Neutral zone, down 4.8 points over five sessions.
54.3Neutral
Down 4.8 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 46 | +0.9% | +2.9% | ||
| Accumulation | 138 | +0.2% | +3.1% | ||
| Neutral (current zone) | 406 | +1.2% | +3.1% | ||
| Distribution | 58 | −0.8% | +1.7% | ||
| Selling | 2 | Too few readings yet | |||
Average ARGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ARGX price, zone by zone.Track ARGX in Gekko
Is argenx stock overvalued? Gekko Fair Value
argenx trades 9.1% below Gekko Fair Value of $1,025.11, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what argenx shares are worth, recalculated every trading day.
$1,025.11
Gekko Fair Value, Oct 31, 2026
9.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ARGX in Gekko
argenx insider and Congress trading
No open-market insider purchases were filed for argenx, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ARGX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ARGX, plotted on the chart in Gekko.Open ARGX in Gekko
Buybacks
argenx has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2024
- $20.08M
- As a share of market cap
- 0.03%
From company filings.
Unusual options activity last 30 days
1signal, 17% of the flagged premium in calls.
Latest: Bearish flow on Oct 23, $1.30M in unusual premium.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold ARGX.
0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
argenx earnings: next date and track record
argenx reports on Feb 25, 2027, before the open (112 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 25, 2027
Expected before the open, 112 days away
- EPS estimate
- $7.70
- Revenue estimate
- $3.35B
8 of 8reports beat the EPS estimate
±7%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- ARGX reported its 18th consecutive quarter of growth in Q2 2026, driven by VYVGART expansion across MG and CIDP indications globally. Key milestone achieved with seronegative gMG approval, making VYVGART the first treatment across all gMG serotypes. Two registrational readouts expected before year-end: autoimmune myositis (Phase III) and empasiprubart in MMN. Pipeline includes 6+ molecules targeting late-stage development by 2030.
- Guidance
- Management targets 10 labeled indications supporting Vision 2030 growth roadmap. Two registrational readouts expected before year-end in myositis and MMN. Rheumatology data expected H2 2027; goal of 5 late-stage molecules by 2030.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $7.32 est $6.27 | $2.82B est $1.88B | +7.8% |
| May 7, 2026 | $5.52 est $4.92 | $2.41B est $1.45B | −3.1% |
| Feb 26, 2026 | $6.79 est $5.95 | — | −6.1% |
| Oct 30, 2025 | $5.18 est $4.37 | $948.0M est $1.28B | −0.4% |
| Jul 31, 2025 | $3.26 est $2.61 | — | +12.5% |
| May 8, 2025 | $2.58 est $2.32 | $573.2M est $861.8M | −11.8% |
| Oct 31, 2024 | $1.39 est $0.10 | $901.9M est $665.1M | +8.0% |
| Jul 25, 2024 | $0.45 est −$0.98 | — | +6.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
argenx stock forecast and analyst price targets
Analysts’ average 12-month price target for argenx is $1,147.35, +23.2% from the last close, from 20 firms rating the stock in the last 90 days.
$1,147.35consensus 12-month target, +23.2% from the last close
Now $931.38Avg $1,147.35
Low $861High $1,400
Each firm’s latest rating in the last 90 days: 20 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 28 | Citi | $1,232 | +32.3% |
| Oct 28 | Bank of America Securities | $1,157 | +24.2% |
| Oct 27 | Citi | $1,232 | +32.3% |
| Oct 25 | Stifel Nicolaus | $1,200 | +28.8% |
| Oct 23 | Morgan Stanley | $1,190 | +27.8% |
+3.1%average 20-day move after past Neutral readings
−0.3%average move over the next 20 trading days in the last 5 years
±3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
argenx seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, argenx averaged −0.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.5% | 2 of 5 |
| Next 10 trading days | −1.5% | 1 of 5 |
| Next 15 trading days | −0.1% | 3 of 5 |
| Next 20 trading days | −0.3% | 3 of 5 |
| Next 30 trading days | 0.0% | 3 of 5 |
For scale, ARGX’s typical 20-trading-day move in either direction is about 5.5%.
argenx market cap and key statistics
argenx’s market cap is $58.57B, with a P/E ratio of 31.1 and revenue of $5.92B over the last twelve months.
Valuation
- Market cap
- $58.57B
- P/E ratio
- 31.1
- Forward P/E
- 25.6
- EPS, TTM
- $28.87
- Gekko Fair Value
- $1,025.11
Trading
- Volume
- 645,794
- Avg volume, 20 days
- 523,616
- 52-week high
- $1,072.75
- 52-week low
- $661.85
- Shares outstanding
- 62.89M
Financials
- Revenue, TTM
- $5.92B
- Profit margin
- 31.7%
- Return on equity
- 23.6%
- Quarterly earnings growth, YoY
- +50.6%
Risk and income
- Beta
- -0.04
- Typical daily move
- ±3%
- Typical 20-day move
- ±5.5%
argenx stock news this week
Coverage of argenx this week reads neutral: 2 positive, 4 neutral and 0 negative headlines.
- Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGXZacks Investment Research, Nov 4
- argenx stock heads to Boston and London investor conferencesad-hoc-news.de, Nov 4
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGXGlobeNewsWire, Nov 3
- Argenx: management expected at two healthcare conferences, in Boston and then LondonIdéal Investisseur, Nov 3
- argenx to Present at Upcoming Investor ConferencesQuantisnow, Nov 3
- Two conference talks will feature argenx leaders in Boston and London.Stock Titan, Nov 3
argenx stock FAQ
What is argenx’s market cap?
argenx’s market cap is $58.57B at the Nov 4, 2026 close of $931.38, with 62.89M shares outstanding. The shares trade on a P/E ratio of 31.1.
What is the argenx stock forecast?
The consensus analyst 12-month price target for argenx is $1,147.35, +23.2% from the last close. Of the 20 firms that rated the stock in the last 90 days, 19 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is argenx stock overvalued or undervalued?
On Gekko’s estimate argenx is undervalued: the Nov 4, 2026 close of $931.38 is 9.1% below Gekko Fair Value of $1,025.11. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does argenx report earnings next?
argenx is expected to report on Feb 25, 2027, before the market opens (112 days away). Analysts expect earnings of $7.70 per share on revenue of $3.35B. argenx beat the earnings estimate in 8 of its last 8 reports, moving 7% on average across the report.
What is argenx’s 52-week high and low?
argenx’s 52-week high is $1,072.75 and its 52-week low is $661.85; it closed at $931.38 on Nov 4, 2026, +12.7% over the past year.
Is argenx stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (fair value and earnings risk), 3 as mixed (trend, gekkoindex and seasonality) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in argenx?
Gekko flagged 1 unusual options signal in argenx over the last 30 days, with $223K of flagged premium in calls and $1.08M in puts. The latest, bearish flow, was on Oct 23, 2026 with $1.30M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See argenx the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.